A research team from Inserm, Lille University, Lille University Hospital, CNRS, and the Institut Pasteur of Lille, as part of the Lille Immunity and Infection Center, is developing a new vaccine against whooping cough. En utilisant la bactérie entière mais génétiquement modifiée pour supprimer sa toxicité, les chercheurs espèrent pallier les défauts d’efficacité du vaccin actuel en induisant une réponse immunitaire durable et en bloquant la transmission bactérienne entre...
Maladie virale à l’origine d’épidémies importantes, principalement en Afrique, la fièvre de la Vallée du Rift (FVR) se transmet du bétail à l’humain. Classée maladie prioritaire émergente par le programme R&D Blueprint de l’Organisation Mondiale de la Santé (OMS) en 2015, sa dynamique de transmission avait pourtant jusqu’ici été peu étudiée. Des chercheurs et professionnels de la santé publique de l’Inserm, de Santé publique France et du Cirad avec...
A research team from Inserm, Lille teaching hospital and Université de Lille working at the Lille Neuroscience and Cognition Laboratory has discovered in mice a mechanism associated with the prepubertal growth spurt and the triggering of early puberty. This mechanism is regulated by the GnRH neurons, which orchestrate fertility, through the expression of their protein Nrp1.
Consuming food products that rank lower on the nutritional quality score underlying the Nutri-Score logo is associated with higher mortality, according to the European cohort EPIC. These findings, obtained by researchers from Inserm, Inrae, Cnam and Université Sorbonne Paris Nord, in collaboration with researchers from the International Agency for Research on Cancer (WHO/IARC), confirm the relevance of Nutri-Score in the context of public health policy.
Les données d'une nouvelle étude confirment que le traitement par hormone de croissance suite à une radiothérapie chez les enfants qui présentent un déficit de cette hormone n’augmente pas le risque de survenue d’un second cancer.
Les résultats d'une méta-analyse montrent qu’un traitement par corticoïdes diminuerait de 21% le risque de mortalité des formes sévères de Covid-19.
Researchers from Inserm, Université d’Evry, Université Paris-Saclay and Genethon have developed a novel platform for modifying the genome of hematopoietic stem cells, which give rise to blood cells. The use of these tools could provide new therapeutic solutions for many patients with rare genetic diseases.
A Marseille-based exploratory research taskforce, named EXPLORE COVID-19, analyzed immune cells in COVID-19 patients at different stages of the disease. The goal of the study was to gain translational insights to better understand the immune response in COVID-19 patients and identify potential targets to fight the viral infection.
While the virus is still circulating throughout the country, fears of a "second wave" are growing. In order to better understand the dynamics of the epidemic, several indicators are taken into account.
As the COVID-19 pandemic continues, finding a treatment to effectively combat the disease remains a major research challenge. Researchers from Inserm, CNRS, Université Claude Bernard Lyon 1 and ENS Lyon at the International Research Center for Infectious Diseases have developed a unique strategy for selecting, evaluating and repurposing existing drugs to assess their efficacy against SARS-CoV-2.
